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In medical treatment, it is necessary to control the behav-
ior of drugs for effective treatment, and many attempts have
been made to deliver drugs to target sites by means of drug
delivery systems. Recently, the use of high-density lipopro-
tein,1) low-density lipoprotein (LDL),2,3) liposomes,4,5) and
lipid emulsions5) as drug carriers have been focused on to
control drug delivery. However, it is difficult to load hy-
drophilic drugs to these hydrophobic carriers because of their
poor affinity. Even if the drug carrier exhibited a favorable
disposition profile, a rapid release of the incorporated drug
often leads to failure to achieve therapeutic potency.4,6)
Sasaki et al.5) and Tokunaga et al.7) demonstrated the drug
delivery of mitomycin C lipophilic prodrugs using liposomes
and/or lipid emulsions. Sqalli-Houssaini et al.8) reported the
drug delivery of lipophilic prodrugs for anti-HIV drugs to
macrophages via LDL pathways. An effective approach to
enhance the affinity of drugs to these hydrophobic carriers
might be using highly lipophilic prodrugs. Therefore, it is
important to evaluate the biodistribution and pharmacokinet-
ics of highly lipophilic prodrugs after intravenous adminis-
tration to develop these lipid carrier systems; however, little
such information has been obtained.
We previously synthesized the O-palmitoyl ester prodrug
of tilisolol (O-palmitoyl tilisolol) and it showed high
lipophilicity compared with tilisolol.9,10) In the present study,
we evaluated the biodistribution and pharmacokinetics after
intravenous administration of O-palmitoyl tilisolol in rats.
Tilisolol, which is a b-blocker, was used as a model drug be-
cause of its easy detection with fluorescence.11)
MATERIALS AND METHODS
Materials Tilisolol hydrochloride was supplied from
Nisshin Flour Milling Co., Ltd. (Tokyo, Japan). All other
chemicals of reagent grade were obtained from Nacalai
Tesque, Inc. (Kyoto, Japan). Phosphate-buffered saline (PBS,
pH 7.4) was prepared by mixing isotonic phosphate buffer
with an equal volume of 0.9% NaCl.
Synthesis of O-Palmitoyl Tilisolol O-Palmitoyl tilisolol
was synthesized according to a method reported previ-
ously.10)
Drug Distribution Ratio between Blood Cells to Plasma
The drug distribution to blood cells was calculated from
blood concentration and plasma concentration. Drugs
(0.005 mmol; 50 m l) dissolved by ethanol were added to rat
whole blood (950 m l) and were incubated at 37 °C for 30 min.
At first, the blood was centrifuged at 12000 g for 5 min. The
drug concentration in blood cells was determined after re-
moval of the plasma. The plasma was ultrafiltrated using a
micropartition system (Ultrafree®-C3, Millipore, Co., Bed-
ford, MA, U.S.A.) at 5000 g for 10 min. The drug concentra-
tion in the preparation (CT) and that in the ultrafiltrate (CW)
were assayed by HPLC. Thus, the equation for the drug bind-
ing ratio to protein was as follows:
binding ratio (%)5
Stability Experiment The blood, plasma and tissues
(liver, kidney, lung, spleen, and heart) for the stability experi-
ments were obtained from rats. The tissues were homoge-
nized on ice in 1.17% KCl with a glass-teflon homogenizer,
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The purpose of this study was to modify the biodistribution and pharmacokinetics of tilisolol, a b-blocker,
using the palmitoyl prodrug approach. After intravenous administration of tilisolol and O-palmitoyl tilisolol in
rats, drug concentrations were determined in blood, bile, urine, and several tissues. The concentration-time pro-
files of tilisolol and O-palmitoyl tilisolol were analyzed pharmacokinetically. The blood concentrations of O-
palmitoyl tilisolol after intravenous administration of O-palmitoyl tilisolol were about 10-fold higher than those
of tilisolol after intravenous administration of tilisolol. The biliary excretion rates of O-palmitoyl tilisolol and
tilisolol after intravenous administration of O-palmitoyl tilisolol were about 10- to 100-fold larger than those of
tilisolol after intravenous administration of tilisolol. In addition, the hepatic uptake clearance of O-palmitoyl
tilisolol after intravenous administration of O-palmitoyl tilisolol was 3.6-fold higher than that of tilisolol after the
intravenous administration of tilisolol. In the in vitro experiments, it was demonstrated that the distribution ra-
tios between blood cells and plasma (blood/plasma) of O-palmitoyl tilisolol and tilisolol was 95.7 and 55.5%, re-
spectively. These findings suggest that O-palmitoyl tilisolol exists as a binding form with biological components,
especially blood cells, in systemic circulation. In conclusion, the palmitoyl prodrug approach is useful as a drug
delivery system to deliver the parent drug to the liver.
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diluted to 10 mg protein/ml with 1.17% KCl. The protein
concentrations were determined by Bio-Rad protein assay
(Bio-Rad Laboratories, Hercules, U.S.A.). The stability ex-
periments of O-palmitoyl tilisolol were performed at 37 °C.
At appropriate time intervals, aliquots of the solution were
withdrawn and subjected to HPLC assay.
In Vivo Experiment Animal experiments conformed to
the Guidelines for Animal Experimentation at Nagasaki Uni-
versity.
Male Wistar rats (220—260 g) were anesthetized with
sodium pentobarbital (50 mg/kg, i.p.), and the left femoral
artery was cannulated with a polyethylene tube (0.5 mm i.d.,
0.8 mm o.d.; Dural Plastics, Dural, Australia). A 3 cm inci-
sion was made in the middle abdomen, and the common bile
duct was cannulated with a polyethylene tube (0.28 mm i.d.,
0.61 mm o.d.; Becton Dickinson, Parsippany, NJ, U.S.A.).
The body temperature of the rats was maintained at 37 °C
with a heat lamp during the experiment. O-Palmitoyl tilisolol
and tilisolol (6 mmol/kg) were injected into the jugular vein.
Then, blood and bile were collected at predetermined time
points. Urine was completely collected at 180 min after intra-
venous administration and diluted 100-folds with distilled
water. The rats were sacrificed by an overdose of sodium
pentobarbital at 30 and 180 min after intravenous administra-
tion, and several organs (liver, kidney, lung, spleen, and
heart) were then excised. The tissues were weighed and ho-
mogenized in an appropriate volume of 1.17% KCl. Aliquots
of blood, bile, urine, and tissue homogenates were used for
the HPLC assay.
Drug Assay for Biological Samples Biological samples
(200 m l for plasma, bile, and urine; 1.5 ml for tissue ho-
mogenates) were shaken with 7 ml of diethyl ether for
15 min, and thereafter centrifuged at 800 g for 10 min. At
first, organic layers containing O-palmitoyl tilisolol were
evaporated. The residues were dissolved in a mixture of 0.1 M
HCl of ethanol (150 m l) and methanol (150 m l) containing an
internal standard (0.03 m l/ml benzyl salicylate). The mixtures
were centrifuged at 12000 g and 80 m l of the supernatant was
injected into the HPLC. For the assay of tilisolol, the aqueous
layers were extracted again with diethyl ether (6 ml) after the
addition of 0.5 M NaOH. The organic layers containing
tilisolol were evaporated, then the residues were dissolved in
0.1 M HCl (100 m l) and methanol (150 m l) containing an in-
ternal standard (300 mg/ml o-ethoxybenzamide). The mix-
tures were centrifuged at 12000 g for 10 min and 80 m l of the
supernatant was injected into the HPLC. The recovery per-
centage for the extraction of tilisolol and O-palmitoyl
tilisolol from blood and each tissue homogenate was approxi-
mately 75%. The detection limit of tilisolol in the blood and
in each tissue homogenate was 0.06 mM. Similarly, the detec-
tion limit of O-palmitoyl tilisolol in the blood and each tissue
homogenate was 0.6 mM.
HPLC An HPLC system (LC-6A, Shimadzu Co., Ltd.,
Kyoto, Japan) with a fluorescence spectromonitor (RF-530,
Shimadzu Co., Ltd., Kyoto, Japan) was used in reverse phase
mode. The excitation wavelength and the emission wave-
length were monitored at 315 and 420 nm, respectively. The
stationary phase used was a Cosmosil 5C18-P packed column
(150 mm length34.6 mm i.d., Nacalai Tesque, Inc., Kyoto,
Japan). For analysis of tilisolol, the mobile phase was
methanol : 50 mM NaH2PO4 (39 : 61, v/v) at a flow rate of
1.0 ml/min. The retention times of tilisolol and o-ethoxyben-
zamide were 4.5 and 11.5 min, respectively. For analysis of
O-palmitoyl tilisolol, the mobile phase was 2-propanol : ace-
tonitrile : 50 mM NaH2PO4 (37 : 33 : 30, v/v) at a flow rate of
1.0 ml/min. The retention times of O-palmitoyl tilisolol and
benzyl salicylate were 10.8 and 4.4 min, respectively.
Pharmacokinetic Analysis Blood profiles of drugs after
intravenous administration were analyzed using a two-com-
partment model. Vc and Vp are the distribution volumes of the
central compartment and the peripheral compartment. Kel is
the first order elimination rate constant from the central com-
partment. K12 and K21 are the first order transfer rate con-
stants between the central compartment and the peripheral
compartment. Pharmacokinetic parameters were calculated
by a nonlinear least squares computer program, MULTI.12)
This program was written by BASIC and run on a personal
computer (PC-9821 V13, NEC, Tokyo, Japan).
Tissue distribution data were evaluated using tissue uptake
clearances as reported previously.13) The change of the drug
amount in tissue with time can be described as follows:
(1)
where T(t) is the amount of drugs in 1 g tissue, C(t) is the
blood concentration of drugs, Clin is the tissue uptake rate
index (clearance) from blood to tissue, and Kout is the efflux
rate constant from the tissues. To estimate the uptake rate
index, distribution in the first 30 min after intravenous ad-
ministration was measured, allowing the contribution of ef-
flux processes and metabolism to be ignored. If efflux is ig-
nored, Eq. 1 is integrated as follows:
(2)
According to Eq. 2, the tissue uptake rate index is calcu-
lated using the amount of drugs in tissue at 30 min and the
area under the blood concentration–time curve (AUC) up to
the time obtained through curve fitting to the blood concen-
tration–time course based on a two-compartment model. Tis-
sue uptake clearance (CLtissue) is expressed as follows:
CLtissue5Clin ·W
where W (g) is the total weight of the tissues.
Statistical Analysis Statistical comparisons were per-
formed by analysis of variance. p,0.05 was considered to be
indicative of statistical significance.
RESULTS AND DISCUSSION
Figures 1A and B shows the stability of O-palmitoyl
tilisolol in blood, plasma, and bile at 37 °C. O-Palmitoyl
tilisolol was rapidly degraded in plasma and bile, and
tilisolol was appeared. The conversion of O-palmitoyl
tilisolol to tilisolol was also observed in blood. In our previ-
ous study, O-palmitoyl tilisolol was converted to tilisolol
even in 40% ethanol of PBS, and its half life was 66.66
3.4 min.10) This result suggested that chemical catalysis con-
tributes to the conversion of O-palmitoyl tilisolol to tilisolol.
In contrast, O-palmitoyl tilisolol was gradually degraded in
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protein binding in the tissue homogenates may cause a sup-
pression of the degradation of lipophilic prodrugs.14) In the
40% ethanol of PBS, blood and each tissue homogenate,
tilisolol appeared to correspond to the degradation extent of
O-palmitoyl tilisolol. However, the extent of tilisolol appear-
ing in bile and plasma was lower than the degradation extent
of O-palmitoyl tilisolol. These results suggest that O-palmi-
toyl tilisolol might be degraded not only to tilisolol but also
to other metabolites in bile and plasma.
The drug concentration profiles in blood after the intra-
venous administration of tilisolol and O-palmitoyl tilisolol
are shown in Fig. 2. Blood concentrations of O-palmitoyl
tilisolol after the intravenous administration of O-palmitoyl
tilisolol were approximately 10-fold higher than that of
tilisolol after the intravenous administration of tilisolol.
Tilisolol was not detected in blood after the intravenous ad-
ministration of O-palmitoyl tilisolol. The blood concentration
profiles of tilisolol and O-palmitoyl tilisolol after the intra-
venous administration of the drugs presented a two-phase
elimination. Therefore, the blood concentration profiles of
drugs were pharmacokinetically analyzed using a two-com-
partment model. The calculated pharmacokinetic parameters
are listed in Table 1. Distribution volumes (Vc and Vp) of O-
palmitoyl tilisolol after intravenous administration of O-
palmitoyl tilisolol were reduced to approximately 5% com-
pared with the distribution volume of tilisolol after the intra-
venous administration of tilisolol. Similarly, Tokui et al. re-
ported that the distribution volume of the palmitoyl prodrug
of rhizoxin was approximately 0.1% compared with the dis-
tribution volume of rhizoxin after the intravenous administra-
tion in mice.3) It was previously reported that macromolecu-
lar prodrugs suppress both the distribution volume and clear-
ance of parent compounds.13) Palmitic acid is a biological
lipid component. Therefore, it is expected that the palmitoyl
functional group may enhance the affinity of the parent drug
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Fig. 1. Remaining O-Palmitoyl Tilisolol (A) and Appearance of Tilisolol (B) in Blood (d), Plasma (m), and Bile (j) at 37 °C; Remaining O-Palmitoyl
Tilisolol (C) and Appearance of Tilisolol (D) in the Liver (d), Kidney (s), Lung (m), Spleen (n), and Heart (h) Homogenates at 37 °C (B)
Each point represents the mean6S.E. of at least three experiments.
Fig. 2. Blood Concentration of Tilisolol (A) and O-Palmitoyl Tilisolol (B)
after Intravenous Administration at a Dose of 6 mmol/kg in Rats
(d) and (s) indicate tilisolol and O-palmitoyl tilisolol, respectively. Fitting line cal-
culated according to a two compartment model. Each point represents the mean6S.E.
of at least three experiments.
Table 1. Pharmacokinetic Parameters of Tilisolol and O-Palmitoyl
Tilisolol after Intravenous Administration in Rats







Vc (l) 0.48360.098 0.03560.004
Vp (l) 2.2760.35 0.10360.011
AUC (mM ·min) 49.5611.2 613693
MRT (min) 83.6611.6 65.5614.4
Each value represents the mean6S.E. of at least three experiments.
on the hydrophobic components in systemic circulation, re-
sulting in increasing their apparent molecular weight.
Table 2 lists the distribution ratios of drugs in rat blood
and plasma at 37 °C at a drug concentration of 5 mM. The dis-
tribution ratio between blood cells and plasma (blood/
plasma) of O-palmitoyl tilisolol was 95.7%. However, the
distribution ratio between blood cells and plasma (blood/
plasma) of tilisolol was 55.5%. These results suggest that O-
palmitoyl tilisolol exists as a form which binds with biologi-
cal components, especially blood cells, in the systemic circu-
lation. It has been reported that lipophilic drugs such as re-
serpine, quinidine, and cyclosporin are strongly bound to
blood cells, albumin, and lipoprotein.14—16) Suda et al. re-
ported that lipophilic prodrugs of 5-fluorouracil were
strongly bound to serum albumin in the rat blood after intra-
venous administration.17) On the other hand, Tokui et al. re-
ported that palmitoyl rhizoxin was effectively bound to LDL
and was delivered to tumors via the LDL pathways.2,3) As
shown in Table 2, O-palmitoyl tilisolol was selectively bound
to blood cells. Erythrocyte ghosts were also demonstrated to
be sustained release carriers for drugs.18) In the present study,
we showed the possibility of a drug delivery system using
erythrocytes by the intravenous administration of palmitoyl
prodrug without preparing the drug/erythrocytes complexes
before intravenous administration.
The biliary excretion rate profiles after intravenous admin-
istration of O-palmitoyl tilisolol and tilisolol were also exam-
ined (Fig. 3). After intravenous administration of O-palmi-
toyl tilisolol, both O-palmitoyl tilisolol and tilisolol were de-
tected in bile. The biliary excretion rates of O-palmitoyl
tilisolol and tilisolol after intravenous administration of O-
palmitoyl tilisolol were approximately 10- to 100-fold higher
than those of tilisolol after the intravenous administration of
tilisolol. Table 3 shows the recovery of drugs in bile and
urine after the intravenous administration of drugs until 180
min. Biliary recovery of O-palmitoyl tilisolol and tilisolol
after intravenous administration of O-palmitoyl tilisolol was
16-fold and 51-fold higher than that of tilisolol after intra-
venous administration of tilisolol, respectively.
After the intravenous administration of tilisolol, most of
the tilisolol was recovered in the urine (Table 3). In contrast,
O-palmitoyl tilisolol and tilisolol after intravenous adminis-
tration of O-palmitoyl tilisolol were scarcely recovered in the
urine. The glomerular filtration of drugs was dependent on
their molecular weights.14) Therefore, the binding of O-
palmitoyl tilisolol to biological components may suppress the
glomerular filtration of O-palmitoyl tilisolol.
Figure 4 shows the drug amounts in various tissues after
intravenous administration of tilisolol and O-palmitoyl
tilisolol at 30 min (A) and 180 min (B). The amounts of O-
palmitoyl tilisolol and tilisolol in the liver and spleen after in-
travenous administration of O-palmitoyl tilisolol were signifi-
cantly higher than that of tilisolol after intravenous adminis-
tration of tilisolol at 30 and 180 min, respectively. The high
amounts of O-palmitoyl tilisolol in these tissues after intra-
venous administration of O-palmitoyl tilisolol may be due to
their high blood concentrations (Fig. 2). Therefore, the tissue
uptake clearances of tilisolol and O-palmitoyl tilisolol after
intravenous administration were calculated (Table 4). The he-
patic uptake clearance of O-palmitoyl tilisolol was 3.6-fold
higher than that of tilisolol. Thus, the tissue uptake clearance
analysis also demonstrated that O-palmitoyl tilisolol was
mainly eliminated from the liver, although large clearances
of tilisolol were observed in the kidney, lung and spleen.
In summary, we examined the biodistribution and pharma-
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Fig. 3. Biliary Excretion Rate of Tilisolol and O-Palmitoyl Tilisolol after
Intravenous Administration of Tilisolol (A) and O-Palmitoyl Tilisolol (B) at
a Dose of 6 mmol/kg in Rats
(d) and (s) indicate tilisolol and O-palmitoyl tilisolol, respectively. Each point rep-
resents the mean6S.E. of at least three experiments.
Table 2. Distribution Ratio between Blood Cells and Plasma of Tilisolol
and O-Palmitoyl Tilisolol in Rat Blood at a Drug Concentration of 5 mM at
37 °C
Plasma (%)
Drugs Blood cells (%)
Bound fraction Free fraction
Tilisolol 55.5 4.0 40.5
O-Palmitoyl tilisolol 95.7 4.3 0
Each value represents the mean of at least three experiments.
Table 3. Recovery in Bile and Urine until 180 min after Intravenous Ad-
ministration of Tilisolol and O-Palmitoyl Tilisolol in Rats
Drugs Bile (%) Urine (%)
Tilisolol 0.1360.02 44.666.8
O-Palmitoyl tilisolol 2.1460.36 0.01560.005
Tilisolol from O-palmitoyl tilisolol 6.6062.06 2.2060.67
Each value represents the mean6S.E. of at least three experiments.
Fig. 4. Biodistribution in Tissue at 30 min (A) and 180 min (B) after Intra-
venous Administration of Tilisolol and O-Palmitoyl Tilisolol at a Dose of
6 mmol/kg in Rats
(h), (j), and ( ) indicate tilisolol, O-palmitoyl tilisolol, and tilisolol from O-
palmitoyl tilisolol, respectively. Statistical comparisons were performed by analysis of
variance (∗ p,0.05, ∗∗ p,0.01). Each value represents the mean6S.E. of at least three
experiments.
cokinetics of O-palmitoyl tilisolol. The blood concentrations
of O-palmitoyl tilisolol after intravenous administration of O-
palmitoyl tilisolol were significantly higher compared with
those of tilisolol after intravenous administration of tilisolol.
In addition, the hepatic uptake clearance of O-palmitoyl
tilisolol after intravenous administration of O-palmitoyl
tilisolol was 3.6-fold higher than that of tilisolol after the in-
travenous administration of tilisolol. In the in vitro experi-
ments, it was demonstrated that the distribution ratios be-
tween blood cells and plasma (blood/plasma) of O-palmitoyl
tilisolol and tilisolol was 95.7 and 55.5%, respectively. These
findings suggested that O-palmitoyl tilisolol exists as a bind-
ing form with biological components, especially blood cells,
in systemic circulation. In conclusion, the palmitoyl prodrug
approach appears to be a useful drug delivery system to de-
liver the parent drug to the liver.
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Table 4. AUC and Tissue Uptake Clearances of Tilisolol and O-Palmitoyl
Tilisolol after Intravenous Administration in Rats
Blood AUC
Tissue uptake clearance (m l/min)
Drugs
(mM ·min)
Liver Kidney Lung Spleen Heart
Tilisolol 17.4 240 1500 840 338 131
O-Palmitoyl tilisolol 265 863 66.9 139 223 24.1
AUC and tissue uptake clearances were calculated for the initial phase until 30 min
after intravenous administration.
